Combination therapy with Dapagliflozin and Ticargrelor prevents diabetes-induced inflammation, renal injury and diabetic cardiomyopathy

Project: Other project

StatusActive
Effective start/end date8/30/175/30/21

Funding

  • AstraZeneca LP: $116,332.00